ARCT-810

· Arcturus Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ARCT-810, covering 2024-08-02 to 2025-09-26. Get the full timeline:

Most recent: Clinical Trial Update: Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 [Phase 2]

See pricing